Tags

Type your tag names separated by a space and hit enter

Bacillus coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study.
Probiotics Antimicrob Proteins. 2020 06; 12(2):335-342.PA

Abstract

Functional constipation has a high prevalence in both adults and children affecting quality of life. Evidence suggests that probiotics can reduce the symptoms of constipation. As the effects of probiotics are strain specific, the efficacy of Bacillus coagulans Unique IS2 in the treatment of functional constipation in adults was evaluated. Subjects (n = 100) diagnosed with functional constipation were supplemented with either B. coagulans Unique IS2 (2 billion CFU) or placebo capsules once daily for 4 weeks. Subjects were evaluated for treatment success (defined as three or more spontaneous stools per week), stool consistency, difficulty of defecation, defecation and abdominal pain. By the end of the fourth week, there was a statistically significant (p < 0.001) increase in number of bowel movements in the probiotic treated group as compared to placebo. Ninety eight percent of subjects in the probiotic group achieved normal stool consistency as compared to placebo (74%). Moreover, there was relief from symptoms of incomplete evacuation, painful defecation and abdominal pain associated with constipation in probiotic treated group as compared to placebo. In conclusion, B. coagulans Unique IS2 significantly decreased the symptoms of constipation indicating effectiveness of the strain in the treatment of constipation.Trial registration: CTRI/2017/11/010539.

Authors+Show Affiliations

Centre for Research and Development, Unique Biotech Ltd., Plot No. 2, Phase II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India. sudha@uniquebiotech.com.Centre for Research and Development, Unique Biotech Ltd., Plot No. 2, Phase II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India.Centre for Research and Development, Unique Biotech Ltd., Plot No. 2, Phase II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India.Department of Paediatrics, MV Hospital and Research Centre, First Floor, Room No. 01 314/30 Mirza Mandi Chowk, Lucknow, Uttar Pradesh, 226003, India.Department of Paediatrics, KRM Hospital and Research Centre, First Floor, Room No. 01 3/92-93 Vijayant Khand, Lucknow, Uttar Pradesh, 226010, India.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30911991

Citation

Madempudi, Ratna Sudha, et al. "Bacillus Coagulans Unique IS2 in Constipation: a Double-Blind, Placebo-Controlled Study." Probiotics and Antimicrobial Proteins, vol. 12, no. 2, 2020, pp. 335-342.
Madempudi RS, Neelamraju J, Ahire JJ, et al. Bacillus coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study. Probiotics Antimicrob Proteins. 2020;12(2):335-342.
Madempudi, R. S., Neelamraju, J., Ahire, J. J., Gupta, S. K., & Shukla, V. K. (2020). Bacillus coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study. Probiotics and Antimicrobial Proteins, 12(2), 335-342. https://doi.org/10.1007/s12602-019-09542-9
Madempudi RS, et al. Bacillus Coagulans Unique IS2 in Constipation: a Double-Blind, Placebo-Controlled Study. Probiotics Antimicrob Proteins. 2020;12(2):335-342. PubMed PMID: 30911991.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bacillus coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study. AU - Madempudi,Ratna Sudha, AU - Neelamraju,Jayanthi, AU - Ahire,Jayesh J, AU - Gupta,Sandeep K, AU - Shukla,Vineet K, PY - 2019/3/27/pubmed PY - 2019/3/27/medline PY - 2019/3/27/entrez KW - Abdominal pain KW - B. coagulans unique IS2 KW - Bowel movements KW - Constipation KW - Probiotic SP - 335 EP - 342 JF - Probiotics and antimicrobial proteins JO - Probiotics Antimicrob Proteins VL - 12 IS - 2 N2 - Functional constipation has a high prevalence in both adults and children affecting quality of life. Evidence suggests that probiotics can reduce the symptoms of constipation. As the effects of probiotics are strain specific, the efficacy of Bacillus coagulans Unique IS2 in the treatment of functional constipation in adults was evaluated. Subjects (n = 100) diagnosed with functional constipation were supplemented with either B. coagulans Unique IS2 (2 billion CFU) or placebo capsules once daily for 4 weeks. Subjects were evaluated for treatment success (defined as three or more spontaneous stools per week), stool consistency, difficulty of defecation, defecation and abdominal pain. By the end of the fourth week, there was a statistically significant (p < 0.001) increase in number of bowel movements in the probiotic treated group as compared to placebo. Ninety eight percent of subjects in the probiotic group achieved normal stool consistency as compared to placebo (74%). Moreover, there was relief from symptoms of incomplete evacuation, painful defecation and abdominal pain associated with constipation in probiotic treated group as compared to placebo. In conclusion, B. coagulans Unique IS2 significantly decreased the symptoms of constipation indicating effectiveness of the strain in the treatment of constipation.Trial registration: CTRI/2017/11/010539. SN - 1867-1314 UR - https://www.unboundmedicine.com/medline/citation/30911991/Bacillus_coagulans_Unique_IS2_in_Constipation:_A_Double_Blind_Placebo_Controlled_Study_ L2 - https://dx.doi.org/10.1007/s12602-019-09542-9 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.